The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANIK | -42.83% | -69.78% | -21.26% | +181% |
| S&P | +12.65% | +91.73% | +13.89% | +1,421% |
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $27.82M | -28.2% |
| Gross Profit | $15.58M | 982.2% |
| Gross Margin | 56.02% | 52.3% |
| Market Cap | $135.53M | -62.9% |
| Market Cap / Employee | $0.47M | 0.0% |
| Employees | 288 | -19.3% |
| Net Income | -$3.18M | 89.4% |
| EBITDA | -$1.83M | 91.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $57.99M | -7.0% |
| Accounts Receivable | $22.19M | -21.8% |
| Inventory | 16.3 | -58.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.78M | -9.7% |
| Short Term Debt | $1.73M | -24.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -6.78% | 28.1% |
| Return On Invested Capital | -3.59% | 3.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.98M | 31.1% |
| Operating Free Cash Flow | $6.87M | 37.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.34 | 1.41 | 1.02 | 0.92 | -54.52% |
| Price to Sales | 1.58 | 1.56 | 1.23 | 1.20 | -45.92% |
| Price to Tangible Book Value | 1.43 | 1.50 | 1.09 | 0.98 | -54.22% |
| Price to Free Cash Flow TTM | 330.87 | 209.16 | - | ||
| Enterprise Value to EBITDA | 288.39 | -69.45 | -46.19 | -55.68 | 283.54% |
| Free Cash Flow Yield | 0.3% | 0.5% | - | ||
| Return on Equity | -20.2% | -20.4% | -22.9% | -8.7% | -79.83% |
| Total Debt | $25.93M | $25.44M | $24.99M | $24.51M | -10.99% |
No podcast episodes available.
ANIK earnings call for the period ending September 30, 2021.
ANIK earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
